arrow
A

Andrea R. Hagemann

washington university in st louis
H指数:29
被引数:4,136

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to ‘OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer’ [Gynecol Oncol 2025 Jun 197 182–191]

勘误:‘OVATION-2:一项评估IMNN-001(IL-12基因疗法)联合新辅助化疗在 newly-diagnosed advanced epithelial ovarian cancer 患者中安全性与有效性的随机I/II期研究’ [Gynecol Oncol 2025 Jun 197 182–191]

2025-11-060
PRE
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

一项关于紫杉醇/卡铂/二甲双胍与紫杉醇/卡铂/安慰剂作为可测量病灶的III期或IVA期、IVB期或复发性子宫内膜癌初始治疗方案的比较研究:一项NRG oncology/GOG研究

2025-04-011
OAAI
Genetic/Familial High-Risk Assessment: Colorectal,Endometrial, and Gastric, Version 3.2024

遗传/家族高危评估:结直肠、子宫内膜和胃,版本 3.2024

2024-12-015
PRE
Stromal cell DDR2 promotes ovarian cancer metastasis
2024-03-040
PRE
A combined RAD51 and phosphorylated replication protein assay predict response to platinum chemotherapy in high-grade serous ovarian cancer
2024-03-040
PRE
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 Featured Updates to the NCCN Guidelines
2023-10-0160
OA
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins
2023-08-017
PRE
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival
2023-07-0315
OAAI
Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer
2022-02-0129
PRE
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
2019-12-19655
OAAI